




MEDISCA® NETWORK INC.
TECHNICAL SUPPORT SERVICES
FORMULATION CHEMISTRY DEPARTMENT
TOLL-FREE: 866-333-7811
TELEPHONE: 514-905-5096
FAX: 514-905-5097
technicalservices@medisca.net

1/29/2023; Page 1

Suggested Formula	Progesterone 40 mg Oral Transmucosal Films (Solid Suspension, 30 Films)	FIN	F 009 669
-------------------	---	-----	-----------

SUGGESTED FORMULATION

Ingredient Listing	Qty.	Unit	NDC #	Supplier	Lot Number	Expiry Date
Progesterone (Micronized), USP	1.200	g				
Bitterness Reducing Agent (NF-01) (Natural) (Powder)	0.25	g				
Menthol (Crystals) (Levorotatory) (Natural), USP	0.06	g				
Sucralose, NF	0.045	g				
Purified Water, USP	8.0	mL				
NovaFilm™ Gel Base	18.00	g				
Purified Water, USP	q.s. to 30.0	mL				





Suggested Formula	Progesterone 40 mg Oral Transmucosal Films (Solid Suspension, 30 Films)	FIN	F 009 669
-------------------	---	-----	-----------

SPECIAL PREPARATORY CONSIDERATIONS

Ingredient-Specific Information

Light Sensitive (protect from light whenever possible):

Progesterone, NovaFilm™ Gel Base

Suggested Preparatory Guidelines

Non-Sterile Preparation Sterile Preparation

Processing Error / Testing Considerations: To account for processing error considerations during preparation, it is suggested to measure an additional **12 to 15%** of the required quantities of ingredients.

Special Instruction: This formula may contain one or more Active Pharmaceutical Ingredients (APIs) that may be classified as hazardous, please refer & verify the current NIOSH list of Antineoplastic and Other Hazardous Drugs in Healthcare Settings. At this time, **General Chapter <800> Hazardous Drugs – Handling in Healthcare Settings** is informational and not compendially applicable unless otherwise specified by regulators and enforcement bodies. For information on the scope, intended applicability, and implementation context for USP General Chapter <800>, see: <https://www.usp.org/compounding/general-chapter-hazardous-drugs-handling-healthcare>.

This formula must be prepared within the appropriate facilities under adequate environmental conditions, following the necessary guidelines and procedures as stated within *USP 795* and *USP 800*, when handling hazardous drugs. Only trained and qualified personnel must prepare this formula.

All required personal protective equipment (hazardous if applicable), such as but not limited to, lab coat, protective sleeves, gloves both inner and outer if applicable, dedicated shoe covers, hairnet, beard cover, eyewear, appropriate face mask, respirator and face shield, etc., where applicable must be worn at all times.

If applicable, follow all required procedures for hazardous drug handling including but not limited to procurement, transport, storage, preparation, dispensing, administration, clean up (spills) & disposal.

If you are a registered 503B facility, please refer to all relevant guidance documents including but not limited to the Code of Federal Regulations (CFR), Guidance for Industry (GFIs) and Compliance Policy Guides (CPGs).

This procedure requires the use of very small quantities of ingredients. All calculations and preparation techniques must be verified before dispensing the final product.



Suggested Formula	Progesterone 40 mg Oral Transmucosal Films (Solid Suspension, 30 Films)	FIN	F 009 669
-------------------	---	-----	-----------

SUGGESTED PREPARATION (for 30 Films)

Weigh and / or measure the following ingredients when appropriate:

Ingredient Listing	Qty.	Unit	Multiplication factor (*): ____	Processing Error	Qty. to measure
Progesterone (Micronized), USP §	1.200	g			
Bitterness Reducing Agent (NF-01) (Natural) (Powder)	0.25	g			
Menthol (Crystals) (Levorotatory) (Natural), USP	0.06	g			
Sucralose, NF	0.045	g			
Purified Water, USP	8.0	mL			
NovaFilm™ Gel Base §	18.00	g			
Purified Water, USP	q.s. to 30.0	mL			

* Takes into account increased batch size conversions and density conversions, if required.

§ Weigh / measure just prior to use.

Preparatory Instruction

1.	<p><u>Preparatory Step:</u></p> <p>A. Preheat an appropriate convection oven.</p> <p><u>Specifications:</u> Temperature: 50°C.</p>
2.	<p><u>Powder-liquid preparation:</u></p> <p>A. By geometric addition, combine and triturate the following ingredients together to form a fine, homogeneous powder blend:</p> <ul style="list-style-type: none"> -Progesterone (Micronized) -Bitterness Reducing Agent (NF-01) (Natural) (Powder) -Menthol (Crystals) (Levorotatory) (Natural) -Sucralose <p>B. Carefully transfer the homogeneous powder blend into a MAZ container.</p> <p>C. Levigate the fine, homogeneous powder blend (Step 2B) with the Purified Water (8.0 mL <i>plus</i> processing error adjustments).</p> <p><u>Specifications:</u> Mix at 2000 RPM or Rotation 9, Revolution 9 for 60 seconds.</p> <p><u>End result:</u> Homogeneous liquid-like dispersion.</p>



Suggested Formula	Progesterone 40 mg Oral Transmucosal Films (Solid Suspension, 30 Films)	FIN	F 009 669
3.	<p><u>Medium incorporation:</u></p> <p>A. Incrementally, add the required quantity of the NovaFilm™ Gel Base into the same MAZ container (Step 2C).</p> <p>B. Add additional Purified Water to the mixture (Step 3A) to fill to the required batch size (30.0 mL <i>plus</i> processing error adjustments) and mix.</p> <p><u>Specifications:</u> Mix at 2000 RPM or Rotation 9, Revolution 9 for 180 seconds.</p> <p><u>End result:</u> Homogeneous gel-like dispersion.</p>		
4.	<p><u>Mold filling and heating:</u></p> <p>A. Fill the 30 blister mold cavities with 1.00 mL of the homogeneous gel-like dispersion (Step 3B) per cavity. Spread the homogeneous gel-like dispersion in the cavity to a uniform thickness.</p> <p><u>NOTE:</u> Ensure no air bubbles are added to the mold cavities.</p> <p>B. Heat the filled blister molds to 50°C for 60 to 90 minutes in the preheated convection oven. Do not overheat.</p> <p><u>Specifications:</u> Homogeneous solid dispersion.</p>		
5.	<p><u>Cooling:</u></p> <p>A. Carefully remove the blister mold from the heated oven.</p> <p>B. Allow the films to cool for an additional 15- 30 minutes in the blister molds. At controlled temperature and relative humidity.</p>		
6.	<p><u>Validation technique:</u></p> <p>A. Weigh 6 films separately.</p> <p>B. The final weight of each film from Step 6A (not including the weight of the blister mold) shall not be less than 90% and not more than 110% of the theoretically calculated weight 0.159 g in accordance to USP guidelines.</p>		
7.	<p><u>Product transfer:</u></p> <p>Transfer the final product into the specified dispensing container (see “Packaging requirements”).</p>		



Suggested Formula	Progesterone 40 mg Oral Transmucosal Films (Solid Suspension, 30 Films)	FIN	F 009 669
-------------------	---	-----	-----------

SUGGESTED PRESENTATION

Estimated Beyond-Use Date		Packaging Requirements	
	180 days, controlled room temperature or refrigerator, as per USP 795*.		Manually lock blister molds and put into light-resistant resealable foil pouch.
Auxiliary Labels	1	Use as directed. Do not exceed prescribed dose.	5 Do not take with alcohol, sleep aids, tranquilizers or other CNS depressants.
	2	Keep out of reach of children.	6 Keep at controlled room temperature (20°C – 25°C) OR keep refrigerated (2°C – 8°C). Do not freeze.
	3	Discard container after use.	7 Protect from light.
	4	May impair mental and/or physical ability. Use care when operating a car or machinery.	8 Consult your health care practitioner if any other prescription or over-the-counter medications are currently being used or are prescribed for future use.
Pharmacist Instructions	Add any auxiliary labels specific to the API to the dispensing container as deemed necessary.		
Patient Instructions	Contact your pharmacist in the event of adverse reactions.		

* If the API or any other components in the CNSP have an expiration date that is earlier than the assigned BUD, the expiration date supersedes the assigned BUD and must be the assigned shortest date.



Suggested Formula	Progesterone 40 mg Oral Transmucosal Films (Solid Suspension, 30 Films)	FIN	F 009 669
-------------------	---	-----	-----------

REFERENCES

1.	Lozenges, Troches, and Films. In: Allen, LV, Jr. <i>The Art, Science, and Technology of Pharmaceutical Compounding Fifth Edition</i> . American Pharmacists Association; 2016: 215.
2.	Crinone. In: Canadian Pharmacists Association. <i>Compendium of Pharmacists and Specialties, 2017</i> : 918.
3.	Menthol. In: Sheskey, P.J., ed. <i>Handbook of Pharmaceutical Excipients, 8th Edition</i> . Pharmaceutical Press and American Pharmacists Association; 2017: 595.
4.	Sucralose. In: Sheskey, P.J., ed. <i>Handbook of Pharmaceutical Excipients, 8th Edition</i> . Pharmaceutical Press and American Pharmacists Association; 2017: 936.
5.	Progesterone. In: Brayfield, A., ed. <i>Martindale: The Complete Drug Reference, 38th Edition</i> . London, England: The Pharmaceutical Press; 2014: 2300.
6.	Progesterone (Monograph). In: O'Neil MJ. <i>The Merck Index 15th Edition</i> . Whitehouse Station, NJ: Merck & Co, Inc.; 2013: Monograph #7889.
7.	Progesterone. In: Trissel LA. <i>Trissel's Stability of Compounded Formulations, 5th Edition</i> . American Pharmaceutical Association; 2012: 409.
8.	Progesterone (Monograph). <i>United States Pharmacopeia XLIII / National Formulary 38</i> . Rockville, MD. US Pharmacopeial Convention, Inc. 2020: 3704.
9.	Progesterone. Thomson Micromedex. <i>USP DI – Drug Information for the Health Care Professional, 26th Edition</i> . Taunton, MA: US Pharmacopeial Convention, Inc; 2006: 2526.
10.	USP <795>. <i>United States Pharmacopeia XLIII / National Formulary 38</i> . Rockville, MD. US Pharmacopeial Convention, Inc. 2020: 7025.

DISCLAIMER: THIS DOCUMENT IS COPYRIGHT© 2022-2023 MEDISCA PHARMACEUTIQUE INC. MEDISCA NETWORK INC., HEREBY REFERRED TO AS 'THE NETWORK', HAS PROVIDED THE FORMULA AND INSTRUCTIONS ABOVE AS A MODEL FOR EDUCATIONAL PURPOSES ONLY ON THE BASIS OF THE RECOGNIZED COMPENDIA AND TEXTS REFERENCED AT THE END OF THIS DOCUMENT. THE NETWORK TAKES NO RESPONSIBILITY FOR THE VALIDITY, SCHEDULING OR ACCURACY OF THIS INFORMATION OR FOR ITS SAFETY OR EFFECTIVENESS, NOR FOR ANY USE THEREOF, WHICH IS AT THE SOLE RISK OF THE LICENSED PHARMACIST OR OTHER APPROPRIATELY STATE LICENSED PROFESSIONAL. ADJUSTMENTS MAY BE NEEDED TO MEET SPECIFIC PATIENT NEEDS AND IN ACCORDANCE WITH A LICENSED PRESCRIBER'S PRESCRIPTION. THE PHARMACIST OR OTHER APPROPRIATELY STATE LICENSED PROFESSIONAL MUST EMPLOY APPROPRIATE TESTS TO DETERMINE THE STABILITY OF THIS SUGGESTED FORMULA. THE NETWORK CANNOT BE HELD LIABLE TO ANY PERSON OR ENTITY CONCERNING CLAIMS, LOSS, OR DAMAGE CAUSED BY, OR ALLEGED TO BE CAUSED BY, DIRECTLY OR INDIRECTLY, THE USE OR MISUSE OF THE INFORMATION CONTAINED IN THIS SUGGESTED FORMULA. IN ALL CASES IT IS THE RESPONSIBILITY OF THE LICENSED PHARMACIST OR OTHER APPROPRIATELY STATE LICENSED PROFESSIONAL TO KNOW THE LAW, TO COMPOUND ANY FINISHED PRODUCT AND TO DISPENSE THESE PRODUCTS IN ACCORDANCE WITH FEDERAL AND STATE LAW. MEDISCA NETWORK INC. MAKES NO WARRANTIES WITH RESPECT TO INFRINGEMENT OR NON-INFRINGEMENT BY THE FORMULA OF ANY PATENT OR OTHER INTELLECTUAL PROPERTY OF ANY OTHER PARTY, AND IT IS THE RESPONSIBILITY OF THE PHARMACIST OR OTHER APPROPRIATELY STATE LICENSED PROFESSIONAL TO INVESTIGATE AND DETERMINE ANY SUCH ISSUE.